Go Blue for Autism

For more information, contact Autism Queensland via enquiries@autismqld.com.au or call (07) 3273 0000

Poster of Go Blue for Autism
Check out our health posters album on Flickr

More Information

On Flickr®

FDA discourages Use of Laparoscopic Power Morcellation for Hysterectomy, Uterine Fibroids Removal

Hysterectomy and procedures to remove uterine fibroids should avoid use of laparoscopic power morcellation, according to a safety advisory from the Food and Drug Administration

DES Action USA communication:
fda logo
Hysterectomy: the FDA discourages Use of Laparoscopic Power Morcellation for Removal of Uterus or Uterine Fibroids.

DES Daughters, with their increased risk for uterine fibroids – pay attention! Find out what your doctor plans to do when surgically treating them. A tool called a power morcellator, that looks and works like the immersion blender found in your kitchen, may inadvertently spread cancer cells while breaking up the fibroid. You may want to be firm with your doctor about options. Sources: here.

Abstract:

Uterine fibroids are noncancerous growths that develop from the muscular tissue of the uterus. Most women will develop uterine fibroids (also called leiomyomas) at some point in their lives, although most cause no symptoms1. In some cases, however, fibroids can cause symptoms, including heavy or prolonged menstrual bleeding, pelvic pressure or pain, and/or frequent urination, requiring medical or surgical therapy.

Many women choose to undergo laparoscopic hysterectomy or myomectomy because these procedures are associated with benefits such as a shorter post-operative recovery time and a reduced risk of infection compared to abdominal hysterectomy and myomectomy2. Many of these laparoscopic procedures are performed using a power morcellator.

A number of additional treatment options are available for women with symptomatic uterine fibroids including traditional surgical hysterectomy (performed either vaginally or abdominally) and myomectomy, laparoscopic hysterectomy and myomectomy without morcellation, laparotomy using a smaller incision (minilaparotomy), deliberate blocking of the uterine artery (catheter-based uterine artery embolization), high-intensity focused ultrasound, and drug therapy. Evidence demonstrates that, when feasible, vaginal hysterectomy is associated with comparable or better results and fewer complications than laparoscopic or abdominal hysterectomy3.

Importantly, based on an FDA analysis of currently available data, it is estimated that 1 in 350 women undergoing hysterectomy or myomectomy for the treatment of fibroids is found to have an unsuspected uterine sarcoma, a type of uterine cancer that includes leiomyosarcoma. If laparoscopic power morcellation is performed in women with unsuspected uterine sarcoma, there is a risk that the procedure will spread the cancerous tissue within the abdomen and pelvis, significantly worsening the patient’s likelihood of long-term survival. For this reason, and because there is no reliable method for predicting whether a woman with fibroids may have a uterine sarcoma, the FDA discourages the use of laparoscopic power morcellation during hysterectomy or myomectomy for uterine fibroids.

Sources:
  • FDA discourages use of laparoscopic power morcellation for removal of uterus or uterine fibroids, FDA, Press Announcements, ucm393689, April 17, 2014
  • Laparoscopic Uterine Power Morcellation in Hysterectomy and Myomectomy: FDA Safety Communication, FDA, Safety Communications, ucm393576, April 17, 2014
  • Uterine Fibroids, NIH Fact Sheets, csid=50, March 29, 2013
  • FDA Warns of Cancer Risk With Laparoscopic Device, MedPage Today, 45309, Apr 17, 2014

Hypermethylation of the HOXA10 Gene, Long-Term altered HOXA10 Expression by in Utero DES Exposure

DES has a dual mechanism of action as an endocrine disruptor

Abstract

image of PubMed NCBI The Endocrine Society logo
In utero DES exposure results in hypermethylation of the HOXA10 gene and long-term altered HOXA10 expression.

Diethylstilbestrol (DES) is a nonsteroidal estrogen that induces developmental anomalies of the female reproductive tract. The homeobox gene HOXA10 controls uterine organogenesis, and its expression is altered after in utero DES exposure. We hypothesized that an epigenetic mechanism underlies DES-mediated alterations in HOXA10 expression. We analyzed the expression pattern and methylation profile of HOXA10 after DES exposure. Expression of HOXA10 is increased in human endometrial cells after DES exposure, whereas Hoxa10 expression is repressed and shifted caudally from its normal location in mice exposed in utero. Cytosine guanine dinucleotide methylation frequency in the Hoxa10 intron was higher in DES-exposed offspring compared with controls (P = 0.017). The methylation level of Hoxa10 was also higher in the caudal portion of the uterus after DES exposure at the promoter and intron (P < 0.01). These changes were accompanied by increased expression of DNA methyltransferases 1 and 3b. No changes in methylation were observed after in vitro or adult DES exposure. DES has a dual mechanism of action as an endocrine disruptor; DES functions as a classical estrogen and directly stimulates HOXA10 expression with short-term exposure, however, in utero exposure results in hypermethylation of the HOXA10 gene and long-term altered HOXA10 expression. We identify hypermethylation as a novel mechanism of DES-induced altered developmental programming.

Sources:
  • Hypermethylation of homeobox A10 by in utero diethylstilbestrol exposure: an epigenetic mechanism for altered developmental programming, NCBI, PMID: 19299448, 2009 Jul;150(7):3376-82. doi: 10.1210/en.2009-0071. Epub 2009 Mar 19
  • Full text – The Endocrine Society, Endocrinology, 10.1210/en.2009-0071, Volume 150 Issue 7 | July 1, 2009.
More DES DiEthylStilbestrol Resources

Food containing Estrogen – The Chemical linked to Obesity and Sexual Dysfunction

Many otherwise healthy foods contain high levels of estrogen

image of Martha Rosenberg
Martha Rosenberg is an investigative health reporter. Her first book, “Born With a Junk Food Deficiency” has just been released.

Estrogen is blamed for many things thing from breast and prostate cancer and other hormone-linked conditions to obesity, sexual dysfunction and dropping sperm counts.
Martha Rosenberg reviews some “good” and “bad” foods that have more estrogen than you may realize—or want.

Read 4 Surprising Foods Packed With Estrogen — The Chemical Linked to Obesity and Sexual Dysfunction, AlterNet, By Martha Rosenberg, April 10, 2014.

Toxic Bodies – Book Video Trailer

Hormone Disruptors and the Legacy of DES, 2010

Toxic Bodies: Hormone Disruptors and the Legacy of DES book trailer by Nancy Langston, Yale University Press, 2010. Video uploaded on 8 Oct 2010 by Nancy Langston.

More DES DiEthylStilbestrol Resources

Interdits d’enfants

En 1998, après avoir découvert l’infertilité de Sylvie, un couple décide de devenir parents grâce à une mère porteuse, pratique illégale en France

Le témoignage unique de parents ayant eu recours à une mère porteuse

Résumé
image de couverture du livre interdits d'enfants
Le témoignage unique de parents ayant eu recours à une mère porteuse

Un couple de Français, Sylvie et Dominique, apprennent qu’ils ne pourront pas avoir d’enfants et décident de partir en Californie pour entamer une procédure de gestation pour autrui (GPA), c’est-à-dire faire appel à une mère porteuse, pratique illégale en France. De retour en France avec leurs jumelles, ils sont assignés en justice pour leurs actes et se battent pour faire valoir leurs droits.

Description de l’ouvrage

Sylvie et Dominique Mennesson sont les symboles malgré eux des révolutions familiales contemporaines. En 1998, après avoir découvert l’infertilité de Sylvie, ce couple décide de devenir parents grâce à une mère porteuse. Cette ” grossesse par procuration ” étant illégale dans notre pays, ils choisissent de se rendre en Californie un État américain précurseur en matière de gestation pour autrui (GPA). Après trois ans d’attente et d’espoirs déçus, Mary, leur gestatrice, donne naissance a deux superbes jumelles, Isa et Léa. Sylvie et Dominique sont enfin parents. Mais, en France, cette filiation est contestée et leurs filles se retrouvent comme des sans papiers, enfants de personne. Le couple va devoir affronter sans relâche la justice française pour être reconnu comme le père et la mère de leurs propres filles. Leur combat, soutenu par des personnalités telles qu’Élisabeth Badinter, Geneviève Delaisi de Parseval ou le professeur François Olivennes, va ébranler bien des certitudes et relancer le débat sur la bioéthique. Interdits d’enfants, l’histoire bouleversante d’une famille trop extraordinaire pour notre société et une réflexion intime sur les nouvelles formes de parenté.

En savoir plus
  • Commentaires en ligne, Amazon
  • CLARA, Comité de soutien pour la Légalisation de la GPA (Gestation Pour Autrui) et l’Aide à la Reproduction Assistée, créé par Sylvie et Dominique Mennesson
  • Gestation pour autrui, un véritable débat doit être mené en France, LeMonde, 07.02.2013
  • Un enfant, la vie : un vrai sujet pour la présidentielle 2012, HuffingtonPost, 10.02.2011
  • Mère porteuse: les Mennesson de retour au tribunal, ParisMatch, 06.04.2011 et Mère porteuse : le combat des Mennesson n’est pas terminé, ParisMatch, 23.03.2010

Sur Flickr®

Autism – SSRI use during Pregnancy linked to ASD and Developmental Delays in Boys

Prenatal SSRI Use and Offspring With Autism Spectrum Disorder or Developmental Delay

JHU Public Health
Johns Hopkins Bloomberg School of Public Health. “Together we’re Protecting Health, Saving Lives – Millions at a Time

In a study of nearly 1,000 mother-child pairs, researchers from the Bloomberg School of Public health found that prenatal exposure to selective serotonin reuptake inhibitors (SSRIs), a frequently prescribed treatment for depression, anxiety and other disorders, was associated with autism spectrum disorder (ASD) and developmental delays (DD) in boys. The study analyzed data from large samples of ASD and DD cases, and population-based controls, where a uniform protocol was implemented to confirm ASD and DD diagnoses by trained clinicians using validated standardized instruments.

Abstract

OBJECTIVE
To examine associations between prenatal use of selective serotonin reuptake inhibitors (SSRIs) and the odds of autism spectrum disorders (ASDs) and other developmental delays (DDs).

METHODS
A total of 966 mother-child pairs were evaluated (492 ASD, 154 DD, 320 typical development [TD]) from the Childhood Autism Risks from Genetics and the Environment (CHARGE) Study, a population-based case-control study. Standardized measures confirmed developmental status. Interviews with biological mothers ascertained prenatal SSRI use, maternal mental health history, and sociodemographic information.

RESULTS
Overall, prevalence of prenatal SSRI exposure was lowest in TD children (3.4%) but did not differ significantly from ASD (5.9%) or DD (5.2%) children. Among boys, prenatal SSRI exposure was nearly 3 times as likely in children with ASD relative to TD (adjusted odds ratio [OR]: 2.91; 95% confidence interval [CI]: 1.07–7.93); the strongest association occurred with first-trimester exposure (OR: 3.22; 95% CI: 1.17–8.84). Exposure was also elevated among boys with DD (OR: 3.39; 95% CI: 0.98–11.75) and was strongest in the third trimester (OR: 4.98; 95% CI: 1.20–20.62). Findings were similar among mothers with an anxiety or mood disorder history.

CONCLUSIONS
In boys, prenatal exposure to SSRIs may increase susceptibility to ASD or DD. Findings from published studies on SSRIs and ASD continues to be inconsistent. Potential recall bias and residual confounding by indication are concerns. Larger samples are needed to replicate DD results. Because maternal depression itself carries risks for the fetus, the benefits of prenatal SSRI use should be carefully weighed against potential harms.

Sources and Study:
  • Johns Hopkins Bloomberg School of Public Health Researchers Find Association Between SSRI Use During Pregnancy and Autism and Developmental Delays in Boys, Johns Hopkins SPH, News Releases, April 15, 2014.
  • Prenatal SSRI Use and Offspring With Autism Spectrum Disorder or Developmental Delay, American Academy of Pediatrics, peds.2013-3406, April 09, 2014.
  • Antidepressant use in pregnancy linked to autism risk in boys: Study, CBC News, HEALTHDAY, April 14, 2014.

Médiator Servier – un Scandale Sanitaire Français en Vingt Dates

La pneumologue brestoise Irène Frachon, à l’origine de la révélation du scandale du Mediator, a souligné que malgré la disparition mercredi de Jacques Servier, “la justice ne s’arrête, et les victimes doivent le savoir”

Récapitulatif

logo de servier
Servier est le premier groupe pharmaceutique indépendant français.
  • 1976: début de la commercialisation du Médiator.
  • Années 1990: premières alertes mais le Médiator reste en vente.
  • 2001: le groupe Servier s’engage à réaliser des études.
  • 2005: retraits du médicament en Europe.
  • 2009: le combat d’Irène Frachon entraîne l’interdiction de commercialisation du Médiator par l’Afssaps.
  • 15 novembre 2010:
    premier bilan de l’Afssaps – on parle de 500 morts.
  • 18 novembre 2010: premières plaintes au pénal.
  • Janvier 2011: (seulement) “trois morts” à cause du Mediator, selon Jacques Servier.
  • 15 janvier 2011:
    le rapport de l’IGAS n’épargne pas le groupe Servier.
  • Janvier 2011: le procès démarre.
  • 7 février 2011: premières perquisitions chez Servier.
  • Eté 2011: mise en place d’un fonds d’indemnisation pour les victimes.
  • 21 septembre 2011: Jacques Servier est mis en examen.
  • Février 2012: l’Afssaps perquisitionnée.
  • 14 mai 2012: le procès est reporté.
  • 22 août 2012: la Cour de cassation rejette la QPC.
  • 11 décembre 2012: Jacques Servier de nouveau mis en examen.
  • Mai 2013:
    faillite du système anti-conflits d’intêrets mise à jour par les juges.
  • 16 avril 2014: décès de Jacques Servier.
  • 17 avril 2014: le processus de la justice continue.

Plus d’informations

  • Médiator, Mort de Javques ServierOlivero, Générique de faim, 17.04.2014.
  • Mort de Servier : “La justice ne s’arrête pas”, selon Irène Frachon, Le Monde, 4402690_1651302, 17.04.2014.
  • Jacques Servier, fondateur du groupe pharmaceutique Servier, est mort, Le Monde, 4402672_3382, 16.04.2014.
  • Les juges qui enquêtent sur le Mediator ont mis au jour la faillite du système anti-conflits d’intêrets
    Le Monde, 3380833_1651302, 20.05.2013.
  • Comprendre l’affaire du Mediator en seize dates, Le Monde, diaporama interactif, 14.05.12.
  • Mediator : un scandale français
    Le Monde, 1466059_3224, 02.02.2011.
  • Mediator, la nouvelle affaire d’Etat qui embarrasse Sarkozy
    Marianne, sarkofrance, 25.12.2010.
  • Distilbène & Médiator, deux époques, deux scandales
    video avec le Dr Irène Frachon, 20.06.2011.

Effect of DiEthylStilboestrol on Gonad Development

Gonadal feminization and feminization of the quail following DES exposure

1st Abstract – 1979

image of PubMed NCBI The Endocrine Society logo
The effect of diethylstilboestrol on gonad development in quail embryos has been quantitatively analysed.

Early treatment of Quail eggs by DES promotes a transient feminization of the gonads in genetic males and a strong stimulation of the Müllerian ducts. The left ovotestis results from the juxtaposition of a testicular medulla and an induced female-type cortex, which develops follicles and a characteristic 17 beta-HSD activity. The right testis is reduced but keeps a consistent structure. The medulla of the treated gonads shows, in both sexes, an inhibition of delta 5-3 beta HSD activity during embryonic development. After hatching, this specific enzyme then develops in the steroidogenic cells. These results are compared with others obtained with estradiol and also in chick. The discussion deals also with the effects of these estrogens on the endogenous abilities and specific responses of the gonads in relation to sex differentiation factors.

2nd Abstract – 1995

The effect of diethylstilboestrol on gonad development in quail embryos has been quantitatively analysed. Quail embryos at 4 days of incubation were treated with diethylstilboestrol (DES), using the egg dipping method. At 10 days of incubation, embryos were removed and killed by decapitation. Tissues were prepared for chromosome analysis, and the parts of the abdomen containing the gonads were prepared for serial sectioning and quantitative assessment. Left gonads of DES-treated male embryos resembled ovaries histologically, while their right gonads were markedly reduced in size. Right gonads of DES-treated female embryos were also further reduced by treatment with DES. There was no statistically significant effect by DES treatment on the size of left gonads, although the ratio of left compared with right gonadal volumes was highly significant. Since, in birds, the left embryonic gonad has ambisexual potential, while the potential of the right gonad is exclusively masculine, these results exemplify the adverse effect exerted by oestrogen on male sexual development in vertebrates.

Sources
  • Feminization of the quail by early diethylstilbestrol treatment: histoenzymological investigations on steroid dehydrogenases in the gonadsNCBI, PMID: 294849, 1979;68(2):85-98.
  • A quantitative investigation of gonadal feminization by diethylstilboestrol of genetically male embryos of the quail Coturnix coturnix japonicaNCBI, PMID: 7616493, 1995 Mar;103(2):223-6.
  • Full text: Journal of Reproduction and Fertility, doi: 10.1530/jrf.0.1030223
More DES DiEthylStilbestrol Resources

How to avoid Bisphenol-A

Exposure to BPA – which binds to our steroid receptors, meaning it can affect estrogen, thyroid and testosterone function – has been underestimated

infographics on how to avoid bpa
Exposure to BPA has been underestimated

We know that the active form of Bisphenol-A (BPA) binds to our steroid receptors, meaning it can affect estrogen, thyroid and testosterone function. A new University of Missouri study shows that the exposure to the controversial chemical BPA through diet has been underestimated by previous lab tests.

Read Exposure to BPA has been underestimated, new MU research says / Bye Bye estrogen, thyroid and testosterone, by Health Research Report, Medical Science not Medical Industry

On Flickr®